Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial

JAMA

Volumn 311, Issue 23, 2014, Pages 2397-2405

  Carvajal, Richard D ^a,b   Sosman, Jeffrey A ^c   Quevedo, Jorge Fernando ^d   Milhem, Mohammed M ^e   Joshua, Anthony M ^f   Kudchadkar, Ragini R ^g   Linette, Gerald P ^h   Gajewski, Thomas F ⁱ   Lutzky, Jose ^j   Lawson, David H ^k   Lao, Christopher D ^l   Flynn, Patrick J ^m   Albertini, Mark R ⁿ   Sato, Takami ^o   Lewis, Karl ^p   Doyle, Austin ^q   Ancell, Kristin ^c   Panageas, Katherine S ^a   Bluth, Mark ^a   Hedvat, Cyrus ^a   Erinjeri, Joseph ^a   Ambrosini, Grazia ^a   Marr, Brian ^a   Abramson, David H ^a,b   Dickson, Mark Andrew ^a,b   Wolchok, Jedd D ^a,b   Chapman, Paul B ^a,b   Schwartz, Gary K ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j Mount Sinai Comprehensive Cancer Center   (United States)

^k EMORY UNIVERSITY   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m Metro Minnesota Community Oncology Research Consortium   (United States)

ⁿ UNIVERSITY OF WISCONSIN MADISON   (United States)

^o THOMAS JEFFERSON UNIVERSITY   (United States)

^p UNIVERSITY OF COLORADO   (United States)

^q NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; SELUMETINIB; TEMOZOLOMIDE;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CANADA; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EYE DISEASE; FACE EDEMA; FATIGUE; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR REGRESSION; UNITED STATES; UVEA MELANOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; DACARBAZINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 84902588435     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.6096     Document Type: Article

References (26)

1. Chang AE, Karnell LH, Menck HR; American College of Surgeons Commission on Cancer and American Cancer Society. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84 836 cases from the past decade. Cancer. 1998;83(8):1664-1678. (Pubitemid 28465486)
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-961. (Pubitemid 36560496)
3. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report No. 15. Arch Ophthalmol. 2001;119(5):670-676.
4. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23(31):8076-8080. (Pubitemid 46657410)
5. Diener-West M, Reynolds SM, Agugliaro DJ, et al; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report No. 26. Arch Ophthalmol. 2005;123(12):1639-1643. (Pubitemid 41785095)
6. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230-5234.
7. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599- 602.
8. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-2199.
9. Ambrosini G, Musi E, Ho AL, de Stanchina E, Schwartz GK. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. Mol Cancer Ther. 2013;12(5):768-776.
10. Ambrosini G, Pratilas CA, Qin LX, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18(13):3552-3561.
11. Khalili JS, Yu X, Wang J, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18(16):4345-4355.
12. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576-1583. (Pubitemid 46450450)
13. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16(5):1613-1623.
14. Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17(8):2087-2100.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
16. Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD. Dropped head syndrome: report of 3 cases during treatment with a MEK inhibitor. Neurology. 2012;79(18):1929-1931.
17. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003;13(3):303-306. (Pubitemid 36683775)
18. Huang MH, Lee JH, Chang YJ, et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013;7(1):112-120.
19. Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- vs BRAF-driven cancers. Nature. 2013;501(7466):232-236.
20. Nissan MH, Pratilas CA, Jones AM, et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014;74(8):2340-2350.
21. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249-256.
22. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368(7):623-632.
23. Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38-47.
24. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine vs placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol. 2013;14(8):733-740.
25. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003;2(8):753-763.
26. Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer. 2013;49(9):2077-2085.